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CD117 expression in diffuse large B-cell lymphomas: 
Fact or fiction?
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Govind Bhagat
Department of Pathology, Columbia University, New York, NY, USA
CD117 (KIT) is expressed in a variety of hematopoietic neo-
plasms but there are a paucity of data regarding its expres-
sion in diffuse large B-cell lymphomas (DLBCL). The
purpose of the present paper was to describe the authors’
experience of two CD117+ DLBCL (one of follicle center-cell
origin and one nasal Epstein–Barr virus (EBV)– plasmablas-
tic lymphoma associated with lytic bone lesions), as deter-
mined by tissue immunohistochemistry and flow cytometry.
The CD117 expression in DLBCL was further evaluated
using tissue microarrays and seven additional plasma-
blastic lymphomas, using two commercially available
anti-CD117 antibodies (Ab-1, Oncogene and A4502, Dako-
Cytomation). Membranous ± cytoplasmic staining was seen
with Ab-1 in 24/65 (37%) DLBCL, including 21/56 microarray
DLBCL, two index cases, and 1/7 additional plasmablastic
lymphomas, with persistent staining in 13% of microarray
DLBCL despite preincubation with KIT peptide. However,
A4502 had only membranous staining of the index cases
and one additional EBV– plasmablastic lymphoma with
medullary disease. The present study suggests that (i)
CD117 expression can be detected sporadically in DLBCL
of follicle center-cell origin and a subset of plasmablastic
lymphomas; (ii) staining for CD117 might help in identifying
EBV– plasmablastic lymphomas associated with bone mar-
row involvement; and (iii) CD117 antibodies should be care-
fully validated prior to use, because non-specific staining,
as observed with Ab-1, could lead to false-positive results.
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The c-kit proto-oncogene encodes a 145–160 kDa trans-
membrane tyrosine kinase receptor (KIT, CD117) that is
physiologically expressed in a variety of cells including mast
cells, hematopoietic stem cells, melanocytes, germ cells, and
the interstitial cells of Cajal.1–3 Activation of KIT by its ligand,
stem cell factor (SCF), plays an important role in the devel-
opment and function of these different cell lineages.4–8
Activating c-kit mutations have been implicated in the
pathogenesis of tumors derived from these cells including
gastrointestinal stromal tumors,9 germ cell tumors,10 mast
cell neoplasms,11 and acute myeloid leukemia (AML).12 KIT
expression has also been documented in other neoplasms,
such as angiomyolipomas,13 small cell lung carcinomas,14
renal cell carcinomas,15 adenoid cystic carcinomas,16
nasopharyngeal carcinomas,17 breast carcinomas,18 and a
variety of pediatric solid tumors.19 The mechanism and tum-
origenic potential of KIT overexpression in these neoplasms
is, however, unclear.
Among hematopoietic neoplasms CD117 expression has
been documented in AML including granulocytic sarco-
mas,2,20 systemic mastocytosis,21 T-cell acute lymphoblastic
leukemia,22 and multiple myeloma.23 Studies have also
reported CD117 expression in cases of classical Hodgkin
lymphoma (cHL), in cHL-derived cell lines, and in anaplastic
large cell lymphoma (ALCL).24,25 More recent reports, how-
ever, have refuted these results and demonstrated that KIT
expression is exceedingly rare in CD30+ lymphomas.26
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of adult non-Hodgkin lymphoma (NHL).27 DLBCL
is a heterogeneous disease entity with variable clinical pre-
sentations, morphology, phenotype, cytogenetic alterations,
and gene expression profiles.28–30 We encountered two cases
of CD117+ DLBCL; one DLBCL of follicle center-cell origin
that presented as a soft-tissue mass in the abdominal wall
of an HIV+ man and the other a plasmablastic lymphoma that
occurred in the nasal cavity of a woman after receiving
chemotherapy for a Helicobacter pylori-associated gastric
DLBCL. Because contradicting results have been published
regarding CD117 expression in lymphomas,24–26 and
because only a few studies have addressed CD117 expres-
sion in DLBCL,20,21,24 we decided to investigate the frequency
of CD117 expression in DLBCL by staining DLBCL tissue
microarrays, as well as seven additional cases of plasma-
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blastic lymphomas, with two different commercially available
anti-CD117 antibodies, both of which recognize an epitope
on the cytoplasmic domain of CD117.
MATERIALS AND METHODS
Tissue microarray design
Two tissue microarray blocks containing a total of 300 cores
from 100 samples representing DLBCL, other B-cell NHL,
cHL, and control tissues were constructed as described pre-
viously.31 In addition to DLBCL (74 cases), the microarrays
contained cores of tissue representing 14 other B-cell NHL
including, follicular lymphoma (FL, n = 2), chronic lympho-
cytic leukemia/small lymphocytic lymphoma (CLL/SLL,
n = 6), marginal zone B-cell lymphoma (MZBCL, n = 2), man-
tle cell lymphoma (MCL, n = 2), and HIV-associated Burkitt
lymphoma (n = 2), two cases of cHL, and 10 controls. The
controls consisted of normal spleen (n = 2), tonsil (n = 2),
brain, thymus, and appendix (one each), and three cell lines
(one Epstein–Barr virus (EBV) transformed lymphoblastoid
cell line, cb33, and two Burkitt cell lines, BurODHI and BurO-
DHIII). Briefly, diagnostic areas were marked on formalin-
fixed, paraffin-embedded tissue blocks from each case. A
tissue arrayer device (Beecher Instrument, Silver Spring, MD,
USA) was used to obtain three 1 mm-diameter cores from
cases and controls. Tissue cores from cases and controls
were then embedded into nascent paraffin blocks.
Additional plasmablastic lymphomas
The seven plasmablastic lymphomas consisted of two EBV+
post-transplant plasmablastic lymphomas (one involving
small bowel mucosa and one subcutaneous tissue of the
forearm), one EBV+ HIV-associated plasmablastic lym-
phoma of the oral cavity, two EBV+ plasmablastic lymphomas
of the nasal cavity, and two EBV– plasmablastic lymphomas
(one involving lymph nodes and spleen and one subcutane-
ous tissue of the chest wall), both of the latter had concurrent
bone marrow involvement.
Histology, immunohistochemistry and 
in situ hybridization
Hematoxylin–eosin (HE) and immunohistochemical (IHC)
staining was performed on 3 µm sections of the index cases,
tissue microarrays and seven plasmablastic lymphomas.
Tonsil and small bowel sections were used as external con-
trols. CD117 staining of all cases was performed after moist
heat-induced antigen retrieval under pressure (citrate buffer,
pH 6.5, microwave 7 min at 100% and 15 min at 40% power
level). Endogenous peroxidase was blocked with 10% hydro-
gen peroxide followed by incubation with swine serum to
inhibit non-specific binding. Two anti-CD117 antibodies were
used: A4502 (rabbit polyclonal, DakoCytomation, Carpinte-
ria, CA, USA) that recognizes an epitope on amino acids
963–973 and Ab-1 (rabbit polyclonal, Oncogene, Cambridge,
MA, USA) that recognizes an epitope on amino acids 961–
976. Two dilutions (1:100 and 1:200 for Ab-1; 1:200 and
1:400 for A4502) were tested on controls and the index cases
with similar results. Thus, only the higher dilutions (1:200 for
Ab-1 and 1:400 for A4502) were used for IHC staining. Stain-
ing was performed on an autostainer (Autostainer Plus,
DakoCytomation) using the Envision plus system (DakoCy-
tomation) for detection.
Specificity of Ab-1 was evaluated by preincubating Ab-1
with a 60-fold excess of KIT peptide (Oncogene) at room
temperature for 2 h prior to staining.
The index cases were stained with additional antibodies
against the following antigens: CD20, Bcl6, CD21, CD138,
CD79a, CD3, latent membrane antigen-1 (LMP-1; DakoCy-
tomation), CD5, CD10 (Novocastra, Burlingame, CA, USA),
Bcl2 and p53 (Biogenex, San Ramon, CA, USA), using stan-
dard methods.
In situ hybridization was performed on the index cases and
additional cases of plasmablastic lymphomas using EBV-
encoded viral RNA (EBER 1-2, Ventana, INFORM EBER,
Tucson, AZ, USA), according to the manufacturer’s protocol.
Scoring of CD117 staining
Semiquantitative assessment of the percentage of cells
stained (PSC) and intensity of staining was performed by the
authors (GB and EV), using a four-tiered scale (1+ − 4+ and
0–3+, respectively). PSC was recorded as 1+, ≤25% of cells
stained; 2+, >25–50% of cells stained; 3+, >50–75% of cells
stained; and 4+, >75% of cells stained. Mast cell staining was
assigned an intensity score of 3+ intermediate intensity of
staining was scored as 2+ while faint staining was scored
as 1+. Only cases with intensity score ≥2+ were considered
positive.
Flow cytometric phenotyping
Four-color flow cytometric analysis (FACScan; Becton Dick-
inson, San Diego, CA, USA) was performed using the Cell
Quest software (Becton Dickinson) according to standard
methods. A phycoerythrin-conjugated anti-CD117 antibody
(mouse, monoclonal, clone 104D2, BD Biosciences, San
Diego, CA, USA) was used that recognizes an extracellular
epitope of CD117. Additional antibodies, directed against the
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following antigens, were used: CD3, CD19, CD20, CD79a
(cytoplasmic), CD10, CD16/56, CD45, CD43, CD34, TdT,




A 60-year-old HIV+ man presented with a soft-tissue mass
of the left lower abdominal wall as well as mesenteric and
retroperitoneal lymphadenopathy. Biopsy of the mass dem-
onstrated a diffuse infiltrate composed predominantly of cen-
troblasts (Fig. 1a), consistent with DLBCL. IHC staining
demonstrated the following phenotype: CD20+, CD10+, bcl-
6+, bcl-2+, CD5–, and CD117+. IHC staining with Ab-1 (not
shown) and A4502 (Fig. 1c) showed similar, albeit variable,
intensity (1+ − 3+) membranous staining in approximately
50% of cells. No staining was seen with Ab-1 after preincu-
bation with KIT peptide. In situ hybridization with EBER was
negative. Flow cytometry confirmed the phenotype, in addi-
tion demonstrating lambda light chain restriction and dim to
moderate CD117 expression in 79% of the neoplastic cells
(Fig. 1e). G-banded analysis demonstrated the translocation
t(14; 18)(q32;q21) in association with a complex karyotype:
47,XY, add(1)(p36),del(1)(q21),3,der(6)t(6;15)(q10;q10),+8,
add(9)(p12), +del(9)(q13), der(13)t(1;13)(q25;q34),t(14;18)
(q32;q21),15 × 2,17,add(17)(p13), +mar1-3[8]/46,XY[13].
Case 2
A 63-year-old woman originally presented with an ulcerated
gastric mass that on biopsy revealed a CD20+, bcl-6+,
CD10(weak, partial)+, CD117– DLBCL associated with
H. pylori infection. Ten months after treatment the patient
developed a nasopharyngeal mass and cervical lymphaden-
opathy. Excisional biopsies showed diffuse, confluent infil-
trates of plasmablasts replacing the cervical lymph node
(Fig. 1b) and a large nodular infiltrate of plasmablasts in the
nasal mucosa, consistent with plasmablastic lymphoma. The
plasmablasts had the following phenotype: CD20–, CD79a+,
bcl-6(weak)+, CD10–, CD138+, CD117+, and LMP-1–. IHC
staining with Ab-1 (not shown) and A4502 (Fig. 1d) showed
1+ − 2+ membranous staining in approximately 30% of cells.
No staining was observed with Ab-1 after preincubation with
KIT peptide. In situ hybridization with EBER was negative.
Flow cytometry confirmed the phenotype, in addition demon-
strating lambda light chain restriction, and dim CD117
expression in 25% of the neoplastic cells (Fig. 1f). G-banded
analysis revealed a complex karyotype: 81–82, <4N>,XX,
-X,-X,-1,-2,der(3)t(1;3)(q21;q27) × 2,4 × 2,+del(6)(q16) × 2,
add(9)(p22),13 × 2, add(14)(q32) × 2,16,17 × 2,+mar1-6[cp5].
Fluorescence in situ hybridization confirmed the IgH rear-
rangement, but there was no evidence of BCL6 or MALT1
rearrangements. There was no evidence of a B-cell NHL or
plasma cell dyscrasia on staging marrow biopsy. Six months
after therapy the patient developed multiple lytic bone lesions
and was found to have a monoclonal serum IgG lambda
paraprotein as well as lambda Bence–Jones protein in the
urine.
CD117 staining of tissue microarrays
Only 76/100 (76%) microarray samples were evaluable due
to partial or complete loss of tissue cores during processing
and/or presence of drying artifact. These cases consisted of
56/74 DLBCL, 10/14 other B-cell NHL (two FL, four CLL/SLL,
two MZBCL, twp MCL), 1/2 cHL, and 9/10 controls (six tissue
controls and three cell lines). Subtypes of DLBCL analyzed
included T-cell/histiocyte rich (n = 2), HIV-associated (n = 2),
post-transplant (n = 4), Richter transformation of CLL (n = 1),
and transformed FL and MZBCL (one case each). Twenty-
one of 56 (21/56, 37%) of the microarray DLBCL stained with
Ab-1 (Table 1). In all positive cases, PSC was either 3+ or
4+. Twelve cases (21%) had 3+ staining intensity (e.g.
Fig. 2b) while nine (16%) had 2+ staining intensity (e.g.
Fig. 2e). In six cases (11%), the pattern of staining was
mixed, cytoplasmic and membranous (e.g. Fig. 2b) while the
rest (15/56, 27%) showed fine granular cytoplasmic staining
(e.g. Fig. 2e). It is important to point out that all the positive
Table 1 CD117 staining of tissue microarray B-cell lymphomas







Staining intensity Pattern of staining
+KIT
peptide2+ 3+ C M and C
Diffuse large B-cell lymphoma 21/56 (37%) 9/56 (16%) 12/56 (21%) 15/56 (27%) 6/56 (10%) 4/30 (13%) 0/56
Classical Hodgkin lymphoma 1/1 1/1 – 1/1 – ND 0/1
Follicular lymphoma 0/2 – – – – 0/2 0/2
Mantle cell lymphoma 0/2 – – – – 0/1 0/2
Marginal zone B-cell lymphoma 0/2 – – – – 0/1 0/2
CLL/SLL 0/4 – – – – 0/2 0/4
C, cytoplasmic; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; M, membranous; ND, not done.
Membranous staining in the absence of cytoplasmic staining was not seen in any of the microarray cases.
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Figure 1 Index cases (a,c,e, case 1; b,d,f, case 2). (a) Diffuse
centroblastic proliferation (HE). (c) Immunohistochemical (IHC)
staining with A4502 (dilution 1:400) demonstrating membranous
staining of the neoplastic cells. (e) Dim to moderate KIT expression
detected by flow cytometry (blue line indicates staining with isotype
matched antibody, a negative control). (b) Diffuse plasmablastic
proliferation in cervical lymph node (HE). (d) IHC staining with A4502
(dilution 1:400) demonstrating membranous staining of plasma-
blasts. (f) Dim KIT expression detected by flow cytometry (blue
line indicates staining with isotype matched antibody, a negative
control) (f).
Figure 2 Representative tissue microarray cases (a–c, example 1; d–f, example 2). (a) HE staining example 1. (b) Immunohistochemical
(IHC) staining with Ab-1 demonstrates 3+ intensity and a cytoplasmic and membranous staining pattern; (c) no staining is seen with A4502.
(d) HE staining example 2. (e) IHC staining with Ab-1 demonstrates 2+ intensity and a cytoplasmic staining pattern; (f) neoplastic cells do
not stain with A4502 but intratumoral mast cells show 3+ staining intensity (arrow).
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(as well as a few negative) cases with Ab-1 had variable
amounts of fine granular staining of the extracellular matrix
and endothelial cells. Mast cells scattered amid neoplastic
cells as well as in control tissue showed intense (3+) mem-
branous as well as variable cytoplasmic staining.
Among the DLBCL subtypes, positive cases included one
case of T-cell/histiocyte rich DLBCL (2+ cytoplasmic stain-
ing), one case of Richter transformation of CLL (3+ cytoplas-
mic staining), and one case of HIV-associated DLBCL (2+
cytoplasmic staining). One case of cHL had 2+ cytoplasmic
staining of Hodgkin and Reed–Sternberg cells but no staining
was observed in any case of FL, CLL/SLL, MCL, or MZBCL
(Table 1). The two Burkitt cell lines were negative, while the
EBV transformed lymphoblastoid cell line had 3+ cytoplasmic
staining.
On IHC staining with Ab-1 after preincubation with KIT
peptide (using one of the tissue microarrays containing 30
evaluable cases of DLBCL), 4/30 cases (13%) showed per-
sistent fine granular cytoplasmic and stromal staining. These
represented 4/14 (29%) of the previously positive cases.
A4502 did not stain any of the tissue microarray cases
(representative examples Fig. 2c,f). Mast cells in control tis-
sues and in lymphoma cases, where present, had 3+ staining
(Fig. 2f).
CD117 staining of additional plasmablastic lymphomas
Only 1/2 of the EBV– (LMP-1–, EBER-) plasmablastic lym-
phomas had 2+ membranous and faint cytoplasmic staining
in approximately 80% of the neoplastic cells with both A4502
and Ab-1. Both of these cases had concurrent marrow
involvement. None of the five EBV+ (LMP-1–, EBER+) plas-
mablastic lymphomas stained with either antibody and none
of these cases had bone marrow disease.
DISCUSSION
KIT/SCF interactions are reportedly not required for normal
B-cell development32 and KIT expression is rare in B-lineage
ALL.2 Only a limited number of studies have analyzed KIT
expression in lymphomas and most of these have focused
on CD30+ lymphomas including cHL and ALCL.24–26 Nat-
kunam and Rouse and Pinto et al. reported a lack of CD117
expression in three and eight cases of DLBCL, respec-
tively,21,24 while Chen et al. reported weak cytoplasmic stain-
ing in 1/28 DLBCL.20 In all these studies, DLBCL were part
of the comparison or control groups where CD117 expres-
sion was being evaluated in other hematopoietic neoplasms.
Nakatsuka et al. reported mutations in exons 11 and 15 in
9/15 adrenal DLBCL, but expression of KIT protein was not
assessed in that study.33
We validated CD117 expression in the present two index
cases with three different antibodies. Tissue staining with
Ab-1 and A4502 demonstrated a membranous staining pat-
tern of variable intensity (Fig. 1c,d) while flow cytometry, with
an antibody directed against an undefined cell surface
epitope, detected dim to moderate KIT expression in both
cases (Fig. 1e,f). In our analysis of DLBCL using tissue
microarrays, however, discordant results were observed with
the two polyclonal CD117 antibodies. Both antibodies are
directed against the carboxy-terminus of the c-kit gene prod-
uct, and have overlapping epitopes. Predominantly cytoplas-
mic staining (Fig. 2b,e) was seen in a significant proportion
(21/56, 37%) of the microarray DLBCL with Ab-1, while none
of these cases stained with A4502. To examine the specificity
of Ab-1, a subset of cases (one tissue microarray containing
30 DLBCL) was incubated with Ab-1 and KIT peptide prior
to staining. Persistent, cytoplasmic (and stromal), fine gran-
ular staining was observed in 4/30 cases (13%) despite
preadsorption with the peptide. Although the presence of KIT
cross-reactive epitopes cannot be entirely excluded in some
DLBCL, we believe that the predominant cytoplasmic stain-
ing pattern, staining of stromal and endothelial cells, and
persistent staining with Ab-1, despite preincubation with KIT
peptide, are features of non-specific binding (by antibodies
directed against KIT as well as other antibodies in the poly-
clonal mixture).
Based on IHC staining results with A4502, CD117 expres-
sion appears to be rare in DLBCL. To confirm this observation
we prospectively analyzed CD117 expression in seven addi-
tional DLBCL by flow cytometry and found all cases to be
negative (data not shown). One of these cases was positive
by IHC staining with Ab-1, but negative with A4502, further
supporting our view of non-specific staining by Ab-1.
Quantification of CD117 mRNA levels was not possible in
any of the DLBCL studied by IHC due to the lack of frozen
tissue availability but we did examine CD117 mRNA expres-
sion levels in another dataset of lymphomas that included 46
DLBCL (including nine HIV-associated), six DLBCL cell lines,
nine Burkitt lymphomas (including seven HIV-associated)
and nine primary effusion lymphomas (Klein U, unpubl. data
2003, available at http://icg.cpmc.columbia.edu/Web_Data/
PEL_Data/Klein_PEL_2003.htm). Interestingly, an elevated
c-kit mRNA level was observed in 1/7 HIV-associated Burkitt
lymphomas (but none of the DLBCL). This is consistent with
the IHC staining results with A4502, confirming the rarity of
CD117 expression in DLBCL.
We tested two different CD117 antibodies because con-
flicting results for KIT expression have been reported for a
subset of lymphomas.24,25,34,35 Pinto et al. detected CD117
expression in a significant number of cHL and ALCL cases
using the monoclonal antibody 17F11 (Immunotech,
Marseille, France), which recognizes an extracellular epitope
of KIT.24,25 In contrast, Rassidakis et al. using the A4502
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antibody, found only one positive ALCL in an analysis of 183
CD30+ lymphomas.26,35 These investigators also reported an
absence of c-kit mRNA expression in seven cHL and five
ALCL cell lines by reverse transcription–polymerase chain
reaction. Using the same antibody (A4502) Brown and Nazmi
reported cytoplasmic staining in 3/10 cases of cHL, nodular
sclerosing subtype, although the dilution of the antibody used
was not reported and no images were available for review.34
It is interesting to note that the single evaluable case of cHL
in the present microarray displayed 2+ cytoplasmic staining
with Ab-1 but did not stain with A4502, similar to the results
of Rassidakis et al.26,35
Disparate staining results for CD117 have also been
reported for other neoplasms, including intra-abdominal des-
moids. Yantiss et al. showed KIT immunoreactivity in 9/12
intra-abdominal desmoids using A4502 (1:30),36 while Hor-
nick and Fletcher using the same antibody at 1:250 dilution
found only focal, weak staining in 1/20 desmoids.37 Similarly,
Miettinen using the rabbit polyclonal antibody sc-168 (Santa
Cruz Biotechnology, San Franscisco, CA, USA) at a 1:400
dilution could not detect staining in 14 tumors analyzed.38 In
an attempt to resolve these disparate results, Lucas et al.
compared two antibodies, C-19 (Santa Cruz Biotechnology),
which recognizes an epitope on amino acids 959–973, and
A4502, at different dilutions.39 They found that the best results
were obtained with A4502 at a dilution of 1:250 and using
these conditions desmoids could be regarded as KIT–
tumors. In our hands an even higher dilution of A4502 (1:400)
provided consistent staining of controls as well as the index
cases, and was, thus, used for higher stringency.
In the present study the discordant results obtained with
the two antibodies, due to false-positive (non-specific) stain-
ing with Ab-1, reinforces the need for critical evaluation of
IHC reagents. False-positive results can pose an important
diagnostic problem. For example, we recently encountered a
case of primary CNS DLBCL (data not shown), which stained
strongly with Ab-1, raising the possibility of a germinoma
before a panel of hematopoietic markers confirmed the diag-
nosis of lymphoma. This lymphoma did not stain with A4502.
To date only rare cases of CD117+ B-cell NHL have been
reported. A single case of a CD117+ CD5+ B-cell NHL car-
rying the translocation t(14; 18)(q32;q21) was reported by
Bravo et al. but these authors did not detect CD117 expres-
sion in a survey of 50 low-grade B-cell chronic lymphoprolif-
erative disorders that included CLL and lymphoplasmacytic
lymphomas.40 CD117 expression has also been observed in
rare cases (1.17%) of mantle cell lymphoma41 but was report-
edly absent in an analysis of 13 Burkitt cell lines and seven
Burkitt lymphomas.42 During preparation of the present
manuscript, Zimpfer et al. published the results of a survey
of CD117 expression in 733 cases of B-NHL (including 385
cases of DLBCL) using antibody A4502 (dilution 1:300).43
They found two CD117+ lymphomas, one case each of folli-
cular lymphoma and peripheral T-cell lymphoma not other-
wise specified, but all DLBCL were negative.
The significance of KIT expression in these cases as well
as in the present index case of DLBCL of follicle center-cell
origin is unclear. No activating mutations of the c-kit gene
were found in the two CD117+ lymphomas reported by
Zimpfer et al.43 A ligand-dependent mode of CD117 upregu-
lation has been proposed for these cases43 and other
CD117+ neoplasms lacking c-kit mutations, including small
cell lung carcinomas and breast carcinomas.44 Variable stain-
ing intensity of only a proportion of cells observed in the
present cases, also favors a secondary inductive effect as
the mechanism responsible for KIT expression (rather than
an activating mutation).
Two of eight (25%) plasmablastic lymphomas analyzed
(including one of the present index cases) were CD117+ on
IHC staining; these represented 2/3 (67%) EBV– plasma-
blastic lymphomas with bone marrow involvement.
Neoplasms with plasmablastic differentiation comprise a het-
erogeneous group of entities that include HIV-associated
lymphomas of the oral cavity (and other sites), primary effu-
sion lymphomas, anaplastic lymphoma kinase+ DLBCL,
Kaposi sarcoma herpes virus-associated lymphomas arising
in the background of plasma cell variant of Castleman’s dis-
ease, a subset of post-transplant lymphomas, and extra-
medullary plasmacytomas.45–49 All these neoplasms share
morphological and phenotypic similarities with subtle varia-
tions. Distinguishing plasmablastic lymphomas from
extramedullary plasmacytomas with plasmablastic morphol-
ogy is not possible with the current armamentarium of mon-
oclonal antibodies.50 The present results, in conjunction with
those of Bayer-Garner et al., suggest that EBV– plasmablas-
tic neoplasms associated with medullary disease or a plasma
cell dyscrasia often express CD117, and, thus, staining for
CD117 might help in differentiating these neoplasms from
other types of plasmablastic lymphomas.51 CD117 is
expressed in a subset of multiple myelomas.23,52 Lemoli et al.
demonstrated a heterogeneous pattern of SCF (kit ligand)
expression and a proliferative response to the same cytokine
by multiple myeloma cell lines,53 suggesting that CD117
expression in a subset of multiple myeloma cases may be
ligand dependent. Moreoever, activating c-kit mutations have
not been identified in the limited number of multiple myeloma
cases analyzed,54 and the efficacy of KIT inhibitors in the
treatment of CD117+ plasma cell neoplasms remains to be
determined.
In conclusion, KIT expression can be seen sporadically in
DLBCL of follicle center-cell origin. Additionally, staining for
CD117 might help in identifying EBV– plasmablastic lympho-
mas associated with medullary disease. Finally, our experi-
ence with the two different CD117 antibodies further
reinforces the need for careful validation of IHC staining for
KIT because of the possible therapeutic implications.
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